In this study, we showed that inflammatory and endothelial dysfunction markers (ADAMTS-13, TNF-α, GDF-15, VEGFA, MPO, and MCP-1) are increased in FD patients’ plasma samples, and can help to evaluate, from a holistic perspective, the risk of disease progression in FD, as well as the response to therapeutic interventions. This evidence concerns the gene VEGFA and Fabry disease.